Neoantigen Targeted Therapies Market Research Report by Target Disease Indication (Bone Cancer, Colorectal Cancer, Gynecological Cancer, Non-small Cell Lung Cancer, and Renal Cell Carcinoma), by Neoantigens Type (Off-the-shelf Neoantigens and Personalized Neoantigens), by Immunotherapy Type, by Route of Administration - Global Forecast to 2025 - Cumulative Impact of COVID-19
Market Statistics:
The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.
1. The Global Neoantigen Targeted Therapies Market is expected to grow from USD 1,255.15 Million in 2020 to USD 6,166.54 Million by the end of 2025.
2. The Global Neoantigen Targeted Therapies Market is expected to grow from EUR 1,100.54 Million in 2020 to EUR 5,406.94 Million by the end of 2025.
3. The Global Neoantigen Targeted Therapies Market is expected to grow from GBP 978.38 Million in 2020 to GBP 4,806.78 Million by the end of 2025.
4. The Global Neoantigen Targeted Therapies Market is expected to grow from JPY 133,956.66 Million in 2020 to JPY 658,126.74 Million by the end of 2025.
5. The Global Neoantigen Targeted Therapies Market is expected to grow from AUD 1,822.64 Million in 2020 to AUD 8,954.64 Million by the end of 2025.
Market Segmentation & Coverage:
This research report categorizes the Neoantigen Targeted Therapies to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Target Disease Indication, the Neoantigen Targeted Therapies Market studied across Bone Cancer, Colorectal Cancer, Gynecological Cancer, Non-small Cell Lung Cancer, and Renal Cell Carcinoma.
Based on Neoantigens Type, the Neoantigen Targeted Therapies Market studied across Off-the-shelf Neoantigens and Personalized Neoantigens.
Based on Immunotherapy Type, the Neoantigen Targeted Therapies Market studied across DNA / RNA-based Vaccines, Dendritic Cell Vaccines, Protein / Peptide-based Vaccines, and TIL-based Therapies.
Based on Route of Administration, the Neoantigen Targeted Therapies Market studied across Intradermal, Intravenous, and Subcutaneous.
Based on Geography, the Neoantigen Targeted Therapies Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Neoantigen Targeted Therapies Market including Aduro Biotech, Inc., Bavarian Nordic, Caladrius Biosciences, Genocea Biosciences, Gradalis, Immunicum, Immunovative Therapies, Iovance Biotherapeutics, Medigene, Neon Therapeutics, Precision Biologics, and Vaxon Biotech.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.
360iResearch FPNV Positioning Matrix:
The 360iResearch FPNV Positioning Matrix evaluates and categorizes the vendors in the Neoantigen Targeted Therapies Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
360iResearch Competitive Strategic Window:
The 360iResearch Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Neoantigen Targeted Therapies Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Neoantigen Targeted Therapies Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Neoantigen Targeted Therapies Market?
4. What is the competitive strategic window for opportunities in the Global Neoantigen Targeted Therapies Market?
5. What are the technology trends and regulatory frameworks in the Global Neoantigen Targeted Therapies Market?
6. What are the modes and strategic moves considered suitable for entering the Global Neoantigen Targeted Therapies Market?
The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.
1. The Global Neoantigen Targeted Therapies Market is expected to grow from USD 1,255.15 Million in 2020 to USD 6,166.54 Million by the end of 2025.
2. The Global Neoantigen Targeted Therapies Market is expected to grow from EUR 1,100.54 Million in 2020 to EUR 5,406.94 Million by the end of 2025.
3. The Global Neoantigen Targeted Therapies Market is expected to grow from GBP 978.38 Million in 2020 to GBP 4,806.78 Million by the end of 2025.
4. The Global Neoantigen Targeted Therapies Market is expected to grow from JPY 133,956.66 Million in 2020 to JPY 658,126.74 Million by the end of 2025.
5. The Global Neoantigen Targeted Therapies Market is expected to grow from AUD 1,822.64 Million in 2020 to AUD 8,954.64 Million by the end of 2025.
Market Segmentation & Coverage:
This research report categorizes the Neoantigen Targeted Therapies to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Target Disease Indication, the Neoantigen Targeted Therapies Market studied across Bone Cancer, Colorectal Cancer, Gynecological Cancer, Non-small Cell Lung Cancer, and Renal Cell Carcinoma.
Based on Neoantigens Type, the Neoantigen Targeted Therapies Market studied across Off-the-shelf Neoantigens and Personalized Neoantigens.
Based on Immunotherapy Type, the Neoantigen Targeted Therapies Market studied across DNA / RNA-based Vaccines, Dendritic Cell Vaccines, Protein / Peptide-based Vaccines, and TIL-based Therapies.
Based on Route of Administration, the Neoantigen Targeted Therapies Market studied across Intradermal, Intravenous, and Subcutaneous.
Based on Geography, the Neoantigen Targeted Therapies Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Neoantigen Targeted Therapies Market including Aduro Biotech, Inc., Bavarian Nordic, Caladrius Biosciences, Genocea Biosciences, Gradalis, Immunicum, Immunovative Therapies, Iovance Biotherapeutics, Medigene, Neon Therapeutics, Precision Biologics, and Vaxon Biotech.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.
360iResearch FPNV Positioning Matrix:
The 360iResearch FPNV Positioning Matrix evaluates and categorizes the vendors in the Neoantigen Targeted Therapies Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
360iResearch Competitive Strategic Window:
The 360iResearch Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Neoantigen Targeted Therapies Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Neoantigen Targeted Therapies Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Neoantigen Targeted Therapies Market?
4. What is the competitive strategic window for opportunities in the Global Neoantigen Targeted Therapies Market?
5. What are the technology trends and regulatory frameworks in the Global Neoantigen Targeted Therapies Market?
6. What are the modes and strategic moves considered suitable for entering the Global Neoantigen Targeted Therapies Market?
1. PREFACE
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome
3. EXECUTIVE SUMMARY
3.1. Introduction
3.2. Market Outlook
3.3. Target Disease Indication Outlook
3.4. Neoantigens Type Outlook
3.5. Route of Administration Outlook
3.6. Immunotherapy Type Outlook
3.7. Geography Outlook
3.8. Competitor Outlook
4. MARKET OVERVIEW
4.1. Introduction
4.2. Cumulative Impact of COVID-19
5. MARKET INSIGHTS
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry
6. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET, BY TARGET DISEASE INDICATION
6.1. Introduction
6.2. Bone Cancer
6.3. Colorectal Cancer
6.4. Gynecological Cancer
6.5. Non-small Cell Lung Cancer
6.6. Renal Cell Carcinoma
7. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET, BY NEOANTIGENS TYPE
7.1. Introduction
7.2. Off-the-shelf Neoantigens
7.3. Personalized Neoantigens
8. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET, BY IMMUNOTHERAPY TYPE
8.1. Introduction
8.2. DNA / RNA-based Vaccines
8.3. Dendritic Cell Vaccines
8.4. Protein / Peptide-based Vaccines
8.5. TIL-based Therapies
9. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET, BY ROUTE OF ADMINISTRATION
9.1. Introduction
9.2. Intradermal
9.3. Intravenous
9.4. Subcutaneous
10. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. South Korea
11.10. Thailand
12. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET
12.1. Introduction
12.2. France
12.3. Germany
12.4. Italy
12.5. Netherlands
12.6. Qatar
12.7. Russia
12.8. Saudi Arabia
12.9. South Africa
12.10. Spain
12.11. United Arab Emirates
12.12. United Kingdom
13. COMPETITIVE LANDSCAPE
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis
13.3. Market Share Analysis
13.4. Competitor SWOT Analysis
13.5. Competitive Scenario
13.5.1. Merger & Acquisition
13.5.2. Agreement, Collaboration, & Partnership
13.5.3. New Product Launch & Enhancement
13.5.4. Investment & Funding
13.5.5. Award, Recognition, & Expansion
14. COMPANY USABILITY PROFILES
14.1. Aduro Biotech, Inc.
14.2. Bavarian Nordic
14.3. Caladrius Biosciences
14.4. Genocea Biosciences
14.5. Gradalis
14.6. Immunicum
14.7. Immunovative Therapies
14.8. Iovance Biotherapeutics
14.9. Medigene
14.10. Neon Therapeutics
14.11. Precision Biologics
14.12. Vaxon Biotech
15. APPENDIX
15.1. Discussion Guide
15.2. License & Pricing
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome
3. EXECUTIVE SUMMARY
3.1. Introduction
3.2. Market Outlook
3.3. Target Disease Indication Outlook
3.4. Neoantigens Type Outlook
3.5. Route of Administration Outlook
3.6. Immunotherapy Type Outlook
3.7. Geography Outlook
3.8. Competitor Outlook
4. MARKET OVERVIEW
4.1. Introduction
4.2. Cumulative Impact of COVID-19
5. MARKET INSIGHTS
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry
6. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET, BY TARGET DISEASE INDICATION
6.1. Introduction
6.2. Bone Cancer
6.3. Colorectal Cancer
6.4. Gynecological Cancer
6.5. Non-small Cell Lung Cancer
6.6. Renal Cell Carcinoma
7. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET, BY NEOANTIGENS TYPE
7.1. Introduction
7.2. Off-the-shelf Neoantigens
7.3. Personalized Neoantigens
8. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET, BY IMMUNOTHERAPY TYPE
8.1. Introduction
8.2. DNA / RNA-based Vaccines
8.3. Dendritic Cell Vaccines
8.4. Protein / Peptide-based Vaccines
8.5. TIL-based Therapies
9. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET, BY ROUTE OF ADMINISTRATION
9.1. Introduction
9.2. Intradermal
9.3. Intravenous
9.4. Subcutaneous
10. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. South Korea
11.10. Thailand
12. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET
12.1. Introduction
12.2. France
12.3. Germany
12.4. Italy
12.5. Netherlands
12.6. Qatar
12.7. Russia
12.8. Saudi Arabia
12.9. South Africa
12.10. Spain
12.11. United Arab Emirates
12.12. United Kingdom
13. COMPETITIVE LANDSCAPE
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis
13.3. Market Share Analysis
13.4. Competitor SWOT Analysis
13.5. Competitive Scenario
13.5.1. Merger & Acquisition
13.5.2. Agreement, Collaboration, & Partnership
13.5.3. New Product Launch & Enhancement
13.5.4. Investment & Funding
13.5.5. Award, Recognition, & Expansion
14. COMPANY USABILITY PROFILES
14.1. Aduro Biotech, Inc.
14.2. Bavarian Nordic
14.3. Caladrius Biosciences
14.4. Genocea Biosciences
14.5. Gradalis
14.6. Immunicum
14.7. Immunovative Therapies
14.8. Iovance Biotherapeutics
14.9. Medigene
14.10. Neon Therapeutics
14.11. Precision Biologics
14.12. Vaxon Biotech
15. APPENDIX
15.1. Discussion Guide
15.2. License & Pricing
LIST OF TABLES
TABLE 1. CURRENCY CONVERSION RATES
TABLE 2. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 3. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 4. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 5. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY BONE CANCER, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 6. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COLORECTAL CANCER, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 7. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GYNECOLOGICAL CANCER, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 8. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 9. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY RENAL CELL CARCINOMA, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 10. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 11. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY OFF-THE-SHELF NEOANTIGENS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 12. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGENS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 13. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 14. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DNA / RNA-BASED VACCINES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 15. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DENDRITIC CELL VACCINES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 16. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PROTEIN / PEPTIDE-BASED VACCINES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 17. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TIL-BASED THERAPIES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 18. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 19. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRADERMAL, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 20. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRAVENOUS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 21. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SUBCUTANEOUS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 22. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 23. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 24. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 25. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 26. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 27. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 28. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 29. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 30. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 31. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 32. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 33. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 34. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 35. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 36. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 37. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 38. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 39. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 40. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 41. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 42. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 43. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 44. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 45. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 46. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 47. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 48. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 49. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 50. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 51. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 52. AUSTRALIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 53. AUSTRALIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 54. AUSTRALIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 55. AUSTRALIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 56. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 57. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 58. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 59. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 60. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 61. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 62. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 63. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 64. INDONESIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 65. INDONESIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 66. INDONESIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 67. INDONESIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 68. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 69. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 70. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 71. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 72. MALAYSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 73. MALAYSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 74. MALAYSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 75. MALAYSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 76. PHILIPPINES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 77. PHILIPPINES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 78. PHILIPPINES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 79. PHILIPPINES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 80. SOUTH KOREA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 81. SOUTH KOREA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 82. SOUTH KOREA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 83. SOUTH KOREA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 84. THAILAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 85. THAILAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 86. THAILAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 87. THAILAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 93. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 94. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 95. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 96. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 97. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 98. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 99. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 100. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 101. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 102. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 103. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 104. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 105. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 106. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 107. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 108. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 109. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 110. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 111. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 112. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 113. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 114. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 115. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 116. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 117. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 118. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 119. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 120. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 121. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 122. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 123. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 124. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 125. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 126. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 127. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 128. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 129. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 130. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 131. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 132. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 133. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 134. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 135. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 136. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 137. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET: SCORES
TABLE 138. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET: BUSINESS STRATEGY
TABLE 139. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET: PRODUCT SATISFACTION
TABLE 140. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET: RANKING
TABLE 141. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET: MERGER & ACQUISITION
TABLE 142. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 143. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 144. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET: INVESTMENT & FUNDING
TABLE 145. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 146. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET: LICENSE & PRICING
TABLE 1. CURRENCY CONVERSION RATES
TABLE 2. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 3. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 4. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 5. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY BONE CANCER, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 6. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COLORECTAL CANCER, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 7. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GYNECOLOGICAL CANCER, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 8. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 9. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY RENAL CELL CARCINOMA, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 10. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 11. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY OFF-THE-SHELF NEOANTIGENS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 12. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGENS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 13. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 14. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DNA / RNA-BASED VACCINES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 15. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DENDRITIC CELL VACCINES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 16. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PROTEIN / PEPTIDE-BASED VACCINES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 17. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TIL-BASED THERAPIES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 18. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 19. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRADERMAL, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 20. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRAVENOUS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 21. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SUBCUTANEOUS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 22. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 23. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 24. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 25. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 26. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 27. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 28. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 29. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 30. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 31. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 32. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 33. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 34. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 35. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 36. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 37. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 38. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 39. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 40. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 41. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 42. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 43. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 44. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 45. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 46. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 47. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 48. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 49. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 50. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 51. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 52. AUSTRALIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 53. AUSTRALIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 54. AUSTRALIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 55. AUSTRALIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 56. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 57. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 58. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 59. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 60. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 61. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 62. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 63. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 64. INDONESIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 65. INDONESIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 66. INDONESIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 67. INDONESIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 68. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 69. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 70. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 71. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 72. MALAYSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 73. MALAYSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 74. MALAYSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 75. MALAYSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 76. PHILIPPINES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 77. PHILIPPINES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 78. PHILIPPINES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 79. PHILIPPINES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 80. SOUTH KOREA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 81. SOUTH KOREA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 82. SOUTH KOREA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 83. SOUTH KOREA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 84. THAILAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 85. THAILAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 86. THAILAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 87. THAILAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 93. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 94. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 95. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 96. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 97. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 98. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 99. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 100. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 101. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 102. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 103. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 104. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 105. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 106. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 107. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 108. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 109. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 110. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 111. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 112. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 113. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 114. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 115. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 116. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 117. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 118. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 119. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 120. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 121. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 122. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 123. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 124. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 125. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 126. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 127. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 128. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 129. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 130. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 131. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 132. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 133. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 134. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 135. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 136. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 137. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET: SCORES
TABLE 138. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET: BUSINESS STRATEGY
TABLE 139. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET: PRODUCT SATISFACTION
TABLE 140. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET: RANKING
TABLE 141. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET: MERGER & ACQUISITION
TABLE 142. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 143. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 144. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET: INVESTMENT & FUNDING
TABLE 145. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 146. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET: LICENSE & PRICING
LIST OF FIGURES
FIGURE 1. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET: RESEARCH EXECUTION
FIGURE 3. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2020 VS 2025 (USD MILLION)
FIGURE 4. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2020 (USD MILLION)
FIGURE 5. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2020 (USD MILLION)
FIGURE 6. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 (USD MILLION)
FIGURE 7. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2020 (USD MILLION)
FIGURE 8. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
FIGURE 9. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 10. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 11. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 12. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 13. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET: MARKET DYNAMICS
FIGURE 14. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 15. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2020 VS 2025 (%)
FIGURE 16. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2020 VS 2025 (USD MILLION)
FIGURE 17. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2025
FIGURE 18. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY BONE CANCER, 2020 VS 2025 (USD MILLION)
FIGURE 19. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COLORECTAL CANCER, 2020 VS 2025 (USD MILLION)
FIGURE 20. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GYNECOLOGICAL CANCER, 2020 VS 2025 (USD MILLION)
FIGURE 21. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2020 VS 2025 (USD MILLION)
FIGURE 22. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY RENAL CELL CARCINOMA, 2020 VS 2025 (USD MILLION)
FIGURE 23. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2020 VS 2025 (%)
FIGURE 24. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2020 VS 2025 (USD MILLION)
FIGURE 25. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2025
FIGURE 26. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY OFF-THE-SHELF NEOANTIGENS, 2020 VS 2025 (USD MILLION)
FIGURE 27. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2020 VS 2025 (USD MILLION)
FIGURE 28. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2020 VS 2025 (%)
FIGURE 29. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2020 VS 2025 (USD MILLION)
FIGURE 30. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2025
FIGURE 31. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DNA / RNA-BASED VACCINES, 2020 VS 2025 (USD MILLION)
FIGURE 32. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DENDRITIC CELL VACCINES, 2020 VS 2025 (USD MILLION)
FIGURE 33. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PROTEIN / PEPTIDE-BASED VACCINES, 2020 VS 2025 (USD MILLION)
FIGURE 34. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TIL-BASED THERAPIES, 2020 VS 2025 (USD MILLION)
FIGURE 35. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 VS 2025 (%)
FIGURE 36. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 VS 2025 (USD MILLION)
FIGURE 37. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025
FIGURE 38. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRADERMAL, 2020 VS 2025 (USD MILLION)
FIGURE 39. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRAVENOUS, 2020 VS 2025 (USD MILLION)
FIGURE 40. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SUBCUTANEOUS, 2020 VS 2025 (USD MILLION)
FIGURE 41. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 42. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 43. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 44. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 45. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 46. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 47. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 48. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 49. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 50. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 51. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 52. AUSTRALIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 53. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 54. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 55. INDONESIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 56. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 57. MALAYSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 58. PHILIPPINES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 59. SOUTH KOREA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 60. THAILAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 61. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 62. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 63. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 64. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 65. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 66. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 67. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 68. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 69. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 70. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 71. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 72. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 73. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 74. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 75. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET: 360IRESEARCH FPNV POSITIONING MATRIX
FIGURE 76. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET: 360IRESEARCH MARKET SHARE ANALYSIS
FIGURE 77. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET: COMPETITOR SWOT ANALYSIS
FIGURE 78. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET, BY TYPE
FIGURE 1. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET: RESEARCH EXECUTION
FIGURE 3. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2020 VS 2025 (USD MILLION)
FIGURE 4. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2020 (USD MILLION)
FIGURE 5. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2020 (USD MILLION)
FIGURE 6. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 (USD MILLION)
FIGURE 7. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2020 (USD MILLION)
FIGURE 8. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
FIGURE 9. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 10. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 11. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 12. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 13. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET: MARKET DYNAMICS
FIGURE 14. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 15. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2020 VS 2025 (%)
FIGURE 16. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2020 VS 2025 (USD MILLION)
FIGURE 17. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2025
FIGURE 18. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY BONE CANCER, 2020 VS 2025 (USD MILLION)
FIGURE 19. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COLORECTAL CANCER, 2020 VS 2025 (USD MILLION)
FIGURE 20. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GYNECOLOGICAL CANCER, 2020 VS 2025 (USD MILLION)
FIGURE 21. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2020 VS 2025 (USD MILLION)
FIGURE 22. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY RENAL CELL CARCINOMA, 2020 VS 2025 (USD MILLION)
FIGURE 23. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2020 VS 2025 (%)
FIGURE 24. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2020 VS 2025 (USD MILLION)
FIGURE 25. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NEOANTIGENS TYPE, 2025
FIGURE 26. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY OFF-THE-SHELF NEOANTIGENS, 2020 VS 2025 (USD MILLION)
FIGURE 27. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGENS, 2020 VS 2025 (USD MILLION)
FIGURE 28. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2020 VS 2025 (%)
FIGURE 29. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2020 VS 2025 (USD MILLION)
FIGURE 30. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY IMMUNOTHERAPY TYPE, 2025
FIGURE 31. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DNA / RNA-BASED VACCINES, 2020 VS 2025 (USD MILLION)
FIGURE 32. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DENDRITIC CELL VACCINES, 2020 VS 2025 (USD MILLION)
FIGURE 33. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PROTEIN / PEPTIDE-BASED VACCINES, 2020 VS 2025 (USD MILLION)
FIGURE 34. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TIL-BASED THERAPIES, 2020 VS 2025 (USD MILLION)
FIGURE 35. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 VS 2025 (%)
FIGURE 36. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 VS 2025 (USD MILLION)
FIGURE 37. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025
FIGURE 38. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRADERMAL, 2020 VS 2025 (USD MILLION)
FIGURE 39. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRAVENOUS, 2020 VS 2025 (USD MILLION)
FIGURE 40. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SUBCUTANEOUS, 2020 VS 2025 (USD MILLION)
FIGURE 41. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 42. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 43. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 44. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 45. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 46. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 47. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 48. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 49. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 50. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 51. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 52. AUSTRALIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 53. CHINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 54. INDIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 55. INDONESIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 56. JAPAN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 57. MALAYSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 58. PHILIPPINES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 59. SOUTH KOREA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 60. THAILAND NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 61. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 62. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 63. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 64. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 65. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 66. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 67. NETHERLANDS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 68. QATAR NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 69. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 70. SAUDI ARABIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 71. SOUTH AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 72. SPAIN NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 73. UNITED ARAB EMIRATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 74. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 75. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET: 360IRESEARCH FPNV POSITIONING MATRIX
FIGURE 76. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET: 360IRESEARCH MARKET SHARE ANALYSIS
FIGURE 77. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET: COMPETITOR SWOT ANALYSIS
FIGURE 78. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET, BY TYPE
